The use of recombinant activated factor VII in trauma patients: experience from the Australian and New Zealand haemostasis registry

Peter A Cameron, Louise Elizabeth Phillips, Zsolt Balogh, Anthony Joseph, Andrew Pearce, Michael Parr, Gary Jankelowitz

Research output: Contribution to journalArticleResearchpeer-review

20 Citations (Scopus)


BACKGROUND: There is increasing use of rFVIIa (eptagog alpha, Novoseven) in injured patients with critical bleeding. The role of rFVIIa is not defined in this group of patients. Registries provide an opportunity to review the patients, reported response and adverse events for rFVIIa. AIM: To determine the pattern of use, reported response and adverse events in patients receiving rFVIIa following injury using the Australian and New Zealand Haemostasis Registry (ANZHR). METHODS: The ANZHR (commenced May 2005) collects data from 53 hospitals on all patients receiving rFVIIa in those hospitals. RESULTS: Of 695 cases in the registry, 108 patients from 19 hospitals were submitted with a primary trauma diagnosis. Most (88) patients received one 90microg/kg dose of rFVIIa. There was a significant reduction in the use of all blood products following rFVIIa (p
Original languageEnglish
Pages (from-to)1030 - 1038
Number of pages9
JournalInjury Extra
Issue number9
Publication statusPublished - 2007

Cite this